Protein composition of cerebrospinal fluid in the developing chick embryo.

W. Fielitz,A. Esteves,R. Moro

DOI: https://doi.org/10.1016/0165-3806(84)90082-8

IF: 3.61

1984-03-01

Brain Research

Abstract:

What problem does this paper attempt to address?

Artificial Classification of Cervical Squamous Lesions in ThinPrep Cytologic Tests Using a Deep Convolutional Neural Network.

Li Liu,Yuanhua Wang,Qiang Ma,Liwen Tan,Yi Wu,Jingjing Xiao

DOI: https://doi.org/10.3892/ol.2020.11974

2020-01-01

Oncology Letters

Abstract:The diagnosis of squamous cell carcinoma requires the accurate classification of cervical squamous lesions in the ThinPrep cytologic test (TCT). It primarily relies on a pathologist's interpretation under a microscope. Deep convolutional neural networks (DCNN) have played an increasingly important role in digital pathology. However, they have not been applied to diverse datasets and externally validated. In the present study, a DCNN model based on VGG16 and an ensemble training strategy (ETS) based on 5-fold cross-validation was employed to automatically classify normal and abnormal cervical squamous cells from a multi-center dataset. First, we collected a dataset comprising 82 TCT samples from four hospitals and fine-tuned our model twice on the dataset with and without the ETS. Then, we compared the classifications obtained from the models with those provided by two skilled pathologists to discriminate the performance of the models in terms of classification accuracy and efficiency. Finally, paired sample t-tests were used to validate the consistency between the classification provided by the proposed methods and that of the pathologists. The results showed that ETS slightly, though not significantly, improved the classification accuracy compared with that of the pathologists: P0=0.387>0.05 (DCNN without ETS vs. DCNN with ETS), P1=0.771>0.05 (DCNN with ETS vs. pathologist 1), P2=0.489>0.05 (DCNN with ETS vs. pathologist 2). The DCNN model was almost 6-fold faster than that of the pathologists. The accuracy of our automated scheme was similar to that of the pathologists, but a higher efficiency in the accurate identification of cervical squamous lesions was provided by the scheme. This result allows for wider and more efficient screening and may provide a replacement for pathologists in the future. Future research should address the viability of the practical implementation of such DCNN models in the laboratory setting.
The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma

Michael H. Roh,Lindsay Schmidt,Jeremiah Placido,Sara Farmen,Kristina L. Fields,Anthony J. Courey,Douglas A. Arenberg,Stewart M. Knoepp

DOI: https://doi.org/10.1002/dc.21680

2011-04-15

Diagnostic Cytopathology

Abstract:The importance of subclassifying pulmonary nonsmall cell carcinoma (NSCLC) in cytologic material is becoming increasingly paramount. Occasionally, cell blocks traditionally used for ancillary studies are sparsely cellular or acellular. Hence, we investigated the diagnostic utility of immunocytochemistry for Napsin-A, TTF-1, and p63 on direct smears of NSCLC. Immunohistochemistry for Napsin-A was initially tested on a tissue microarray (TMA) composed of pulmonary adenocarcinoma. Subsequently, in 25 cases, immunocytochemistry for Napsin-A, TTF-1, and p63 was performed on cytologic direct smears. Smears were prepared from tumor cells scraped from lung resection specimens (n = 10), endobronchial ultrasound-guided transbronchial fine-needle aspirates (n = 13), and pelleted cell material from pleural effusions (n = 2). Immunohistochemistry utilizing the TMA revealed Napsin-A positivity in 73% of pulmonary ADCs. Next, immunocytochemistry on direct cytologic smears demonstrated a Napsin-A(+)/TTF-1(+) immunophenotype in 15 of 18 adenocarcinomas; p63 was completely negative (n = 12) or only focally positive (n = 3) in these 15 adenocarcinomas. The remaining three adenocarcinomas were negative for all three markers. All six squamous cell carcinomas were Napsin-A(-)/TTF-1(-) and diffusely p63(+). In conclusion, direct smears represent a feasible and robust source of cellular material for immunocytochemical studies to diagnose pulmonary ADC and SQC. Our method allows the cytologist to confirm on site that material for diagnostic immunocytochemistry is present thereby serving as a safeguard in instances where the cell block is of insufficient cellularity.

pathology,medical laboratory technology
Diagnostic and Predictive Immunocytochemistry in Lung Cancer

Deepali Jain,Shraddhanjali Satapathy,Lukas Bubendorf

DOI: https://doi.org/10.1159/000541478

2024-09-19

Abstract:Background: Immunocytochemistry (ICC) is suitable for use on a range of cytology preparations, such as cell blocks, air-dried slides, ethanol-fixed slides, direct smears, cytospins, and liquid-based cytology (LBC) samples. However, it must be standardized against the gold standard of formalin-fixed paraffin-embedded tissues with adequate number of positive and negative controls. The role of ICC in lung cancer is crucial, as most lung cancer specimens are cytology samples. Accurate diagnosis and testing of certain biomarkers rely heavily on both diagnostic and predictive ICC. Summary: Key ICC markers important in lung cancer include, but are not limited to, diagnostic ICCs such as TTF-1, p40, Napsin A, and p63, as well as predictive ICCs like ALK, ROS-1, PD-L1, and NTRK. Key messages: With proper validation, immunocytochemistry for lung cancer can be effectively performed on direct smears, cytospins, and other specimens, even when resources for preparing cell blocks are unavailable. This is particularly true for diagnostic antibodies, but it is important to exercise caution with predictive ICC. Nonetheless, a low threshold for molecular testing should be maintained. PD-L1 ICC can be challenging and should ideally be performed on formalin-fixed cell blocks or biopsies when available.
Recommendations for immunocytochemistry in lung cancer typing: An update on a resource-efficient approach with large-scale comparative Bayesian analysis

Hatice Elmas,Roland Diel,Binnur Önal,Guido Sauter,Florian Stellmacher,Lutz Welker

DOI: https://doi.org/10.1111/cyt.13051

Cytopathology

Abstract:Objectives: The majority of lung cancer cases are of advanced stage and diagnosis is usually made using minimally invasive small biopsies and cytological specimens. The WHO 2015 classification recommends limiting immunocytochemistry (ICC) to lung cancer typing and molecular testing drives for personalised therapies. An algorithm using Bayes' theorem could be useful for defining antibody profiles. This study aims to assess the impact of different antibody profiles for cytological samples on the accuracy of lung cancer typing with a large-scale Bayesian analysis. Methods: A retrospective examination of 3419 consecutive smears and/or cytospins diagnosed over 2011-2016 found 1960 primary lung cancer tumours: 972 adenocarcinomas (ADC), 256 squamous carcinomas (SQC), 268 neuroendocrine tumours (NET), and 464 non-small cell cancer-not otherwise specified (NSCC-NOS). The a priori and a posteriori probabilities, before and after ICC using antibodies singly or in combination, were calculated for different lung cancer types. Results: TTF-1 or CK7 alone improved the a posteriori probabilities of correct cytological typing for ADC to 86.5% and 95.8%, respectively. For SQC, using p40 (∆Np63) or CK5/6 together with CK5/14 led to comparable results (78.3% and 90.3%). With synaptophysin or CD56 alone, improvements in a posteriori probabilities to 87.5 and 90.3% for the correct recognition of NET could be achieved. Conclusions: Based on morphological and clinical data, the use of two antibodies appears sufficient for reliable detection of the different lung cancer types. This applies to diagnoses that were finalised following ICC both on a clinical or cytological basis and on a histological basis.
Immunocytochemistry for predictive biomarker testing in lung cancer cytology

Deepali Jain,Aruna Nambirajan,Alain Borczuk,Gang Chen,Yuko Minami,Andre L. Moreira,Noriko Motoi,Mauro Papotti,Natasha Rekhtman,Prudence A. Russell,Spasenija Savic Prince,Yasushi Yatabe,Lukas Bubendorf,the IASLC Pathology Committee,

DOI: https://doi.org/10.1002/cncy.22137

2019-05-01

Cancer Cytopathology

Abstract:With an escalating number of predictive biomarkers emerging in non–small cell lung carcinoma (NSCLC), immunohistochemistry (IHC) is being used as a rapid and cost‐effective tool for the screening and detection of many of these markers. In particular, robust IHC assays performed on formalin‐fixed, paraffin‐embedded (FFPE) tumor tissue are widely used as surrogate markers for ALK and ROS1 rearrangements and for detecting programmed death ligand 1 (PD‐L1) expression in patients with advanced NSCLC; in addition, they have become essential for treatment decisions. Cytology samples represent the only source of tumor in a significant proportion of patients with inoperable NSCLC, and there is increasing demand for predictive biomarker testing on them. However, the wide variation in the types of cytology samples and their preparatory methods, the use of alcohol‐based fixatives that interfere with immunochemistry results, the difficulty in procurement of cytology‐specific controls, and the uncertainty regarding test validity have resulted in underutilization of cytology material for predictive immunocytochemistry (ICC), and most cytopathologists limit such testing to FFPE cell blocks (CBs). The purpose of this review is to: 1) analyze various preanalytical, analytical, and postanalytical factors influencing ICC results; 2) discuss measures for validation of ICC protocols; and 3) summarize published data on predictive ICC for ALK, ROS1, EGFR gene alterations and PD‐L1 expression on lung cancer cytology. Based on our experience and from a review of the literature, we conclude that cytology specimens are in principal suitable for predictive ICC, but proper optimization and rigorous quality control for high‐quality staining are essential, particularly for non‐CB preparations.

oncology,pathology
Nonlinear and Time-Varying Dynamical Models of Human Operators in Manual Control Systems

W. Wierwille,G. A. Gagne

DOI: https://doi.org/10.1177/001872086600800201

1966-04-01

Abstract:This paper describes the application of a deterministic theory for characterizing or modeling the dynamics of a human operator in a manual control system. Linear time-varying, nonlinear time-varying, and non-linear constant-coefficient models are obtained by applying the theory to tracking data taken for one- and two-axis tasks with various displays. The accuracy and fidelity of these advanced models are explored in detail. Also, new information about time variability and nonlinearity of the human operator, obtained by studying the models and the manual control system signals, is presented.
A technique to improve diagnostic information from fine-needle aspirations: immunohistochemistry on cytoscrape

Birgit Guldhammer Skov,Katalin Kiss,Julie Ramsted,Dorte Linnemann

DOI: https://doi.org/10.1002/cncy.20005

IF: 6.9209

2009-04-25

Cancer

Abstract:Background: Cytologic examination of fine-needle aspiration (FNA) material is being used increasingly for the diagnosis of pulmonary lesions. Accurate distinction between nonsmall cell lung cancer (NSCLC), including subgroups, and small cell lung cancer and between primary lung cancer and metastases has therapeutic impact. However, the distinction between these groups may be difficult on smears. In this report, the authors describe a simple method, called cytoscrape (CS), which can be used on virtually any smear to produce material useful for ancillary methods, including immunohistochemistry. Methods: Aspirates from 47 patients who had possible malignant infiltrates identified on computed tomography scans of the chest were included. Smears were stained by May-Grunwald-Giemsa and Diff-Quick for diagnostic purposes. CS material was obtained by gently scraping cells off the slides. Clots were made, and the sections were stained for thyroid transcription factor-1 (TTF-1) and mucin. The utility of the CS technique was evaluated by assessing the sensitivity and specificity of the method and by quantifying the extra diagnostic information obtained by the method relative to smears alone. Results: Malignant tumor cells in the CS material were identified in 43 aspirates (91%). Both the sensitivity and the specificity for TTF-1 were 100%. The sensitivity for mucin was 60%, and the specificity for mucin was 100%. The diagnoses made on smears were improved by CS in 31 patients (72%), in that more precise separation of subgroups of NSCLC was possible or information on primary tumors was obtained. Conclusions: The CS technique improved the diagnostic information from FNA in a clinically relevant way. The method is simple, quick, and inexpensive.
Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans.

Yoshitsugu Miyazaki,A. Geber,Haruko Miyazaki,D. Falconer,Tanya Parkinson,Christopher A. Hitchcock,Brian T. Grimberg,Katherine Nyswaner,John E. Bennett

DOI: https://doi.org/10.1016/S0378-1119(99)00263-2

IF: 3.913

1999-08-05

Gene

Abstract:
PUB015 the Use of Immunohistochemistry Improves the Diagnosis of SCLC. an International Reproducibility Study in a Demanding Set of Cases

Erik Thunnissen,Alain Borczuk,Douglas Flieder,Birgit Witte,Mary Beasley,Jin-Haeng Chung,Sanja Dacic,Sylvie Lantuejoul,Prudence Russell,Michael Den Bakker,Johan Botling,Elisabeth Brambilla,Erienne De Cuba,Kim Geisinger,Kenzo Hiroshima,Alberto Marchevsky,Yuko Minami,Andre Moreira,Andrew Nicholson,Akihiko Yoshida,Ming Tsao,Arne Warth,Edwina Duhig,Gang Chen,Yoshihiro Matsuno,William Travis,Kelly Butnor,Wendy Cooper,Mari Mino-Kenudson,Noriko Motoi,Claudia Polari,Giuseppe Pelosi,Keith Kerr,Yuichi Ishikawa,Reinhard Buettner,Naoto Keino,Yasushi Yatabe,Masayuki Noguchi

DOI: https://doi.org/10.1016/j.jtho.2016.11.1985

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:The current World Health Organization (WHO) classification of lung cancer states that a diagnosis of small cell lung carcinoma (SCLC) can be reliably made on routine histological and cytological grounds, but immunohistochemistry may be required for confirmation of neuroendocrine and epithelial nature of the tumor cells. In addition, in small biopsies, the proliferation activity of SCLC as assessed by Ki-67 antigen immunostaining should be performed to avoid misdiagnosing carcinoid tumors in the presence of crush artifact. However, reproducibility studies on H&E alone for SCLC versus large cell neuroendocrine carcinoma have shown pairwise kappa scores ranging from 0.35 – 0.81. In the diagnostic process of SCLC, IHC may be useful i) in cases where histologic features are equivocal and ii) in cases where the pathologist wants to gain confidence. This study examines whether judicious use of immunohistochemistry (IHC) improves diagnostic reproducibility for SCLC. Nineteen lung pathologists studied interactive digital images of 79 tumors predominantly neuroendocrine lung tumors. Resection and biopsy sample images were diagnosed solely on morphology (level 1), morphology along with requested immunohistochemical stains (level 2), and with all available immunohistochemical stains (level 3). For the 19 pathologists reading all 79 cases the agreement rate for level 1 was 64.7% and increased to 73.2% and 77.5% in levels 2 and 3, respectively. With IHC, kappa scores for four tumor categories (SCLC, LCNEC, carcinoid tumors, and other) increased in resection samples from 0.43 to 0.60 and in biopsy samples from 0.43 to 0.64. An approach for IHC in the differential diagnosis of SCLC is provided and needs further confirmation, preferably linked to treatment outcome. In this set of challenging cases H&E stand alone diagnosis on “neuroendocrine appearing” tumors performs well, but is improved in most cases by the judicious use of IHC in the diagnosis of SCLC, where histologic features are equivocal or when the pathologist wants to gain confidence.
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases

Erik Thunnissen,Alain C. Borczuk,Douglas B. Flieder,Birgit I. Witte,Mary Beth Beasley,Jin Haeng Chung,Sanja Đačić,Sylvie Lantuéjoul,Prudence A. Russell,Michael den Bakker,Johan Botling,Élisabeth Brambilla,Erienne de Cuba,Kim R. Geisinger,Kenzo Hiroshima,Alberto M. Marchevsky,Yuko Minami,André L. Moreira,Andrew G. Nicholson,Akihiko Yoshida,Ming‐Sound Tsao,Arne Warth,Edwina Duhig,Gang Chen,Yoshihiro Matsuno,William D. Travis,Kelly J. Butnor,Wendy A. Cooper,Mari Mino–Kenudson,Noriko Motoi,Claudia Poleri,Giuseppe Pelosi,Keith M. Kerr,Seena C. Aisner,Yuichi Ishikawa,Reinhard Buettner,Naoto Keino,Yasushi Yatabe,Masayuki Noguchi

DOI: https://doi.org/10.1016/j.jtho.2016.12.004

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:IntroductionThe current WHO classification of lung cancer states that a diagnosis of SCLC can be reliably made on routine histological and cytological grounds but immunohistochemistry (IHC) may be required, particularly (1) in cases in which histologic features are equivocal and (2) in cases in which the pathologist wants to increase confidence in diagnosis. However, reproducibility studies based on hematoxylin and eosin–stained slides alone for SCLC versus large cell neuroendocrine carcinoma (LCNEC) have shown pairwise κ scores ranging from 0.35 to 0.81. This study examines whether judicious use of IHC improves diagnostic reproducibility for SCLC.MethodsNineteen lung pathologists studied interactive digital images of 79 tumors, predominantly neuroendocrine lung tumors. Images of resection and biopsy specimens were used to make diagnoses solely on the basis of morphologic features (level 1), morphologic features along with requested IHC staining results (level 2), and all available IHC staining results (level 3).ResultsFor the 19 pathologists reading all 79 cases, the rate of agreement for level 1 was 64.7%, and it increased to 73.2% and 77.5% in levels 2 and 3, respectively. With IHC, κ scores for four tumor categories (SCLC, LCNEC, carcinoid tumors, and other) increased in resection samples from 0.43 to 0.60 and in biopsy specimens from 0.43 to 0.64.ConclusionsDiagnosis using hematoxylin and eosin staining alone showeds moderate agreement among pathologists in tumors with neuroendocrine morphology, but agreement improved to good in most cases with the judicious use of IHC, especially in the diagnosis of SCLC. An approach for IHC in the differential diagnosis of SCLC is provided.
Accuracy of Classifying Lung Carcinoma Using Immunohistochemical Markers on Limited Biopsy Material: A Two-Center Study

Amber Hassan,Shadi Alahmadi,Omer Waqas,Humaira Waseem,Amer Shafie Abdelrahman,Majid Almansouri,Nasser Mulla,Yousef Katib,Salwa I Bakhsh,Mohammed Basheikh,Samy A Abusikkien,Mohamed Matoog Karami,Marwan Al-Hajeili,Samah S Elbasateeny

DOI: https://doi.org/10.7759/cureus.32956

2022-12-26

Cureus

Abstract:Introduction Accurate classification of lung cancer into primary and metastatic carcinomas is critical for treatment approaches. Immunohistochemistry (IHC) has always been pivotal in unveiling the diverse cell differentiation lineages present in lung cancer by using specific biomarkers such as TTF1 and p63/p40, which closely reflect the relationship between genotype and phenotype.. Methods A retrospective cross-sectional study was conducted to evaluate 57 Tru-Cut biopsies over two years, from 2020-2022. Tumour morphology was evaluated, and IHC for TTF-1, Napsin A, CK-7, P-63, P-40, and CD-56 was performed in two steps. Results Of the lung cancer cases, 58.5% were adenocarcinoma (ADC), 24.5% were squamous cell carcinoma (SCC), 9.4% were small cell carcinoma, and 7.5% were poorly differentiated carcinoma. TTF1 stain had sensitivity and specificity of 78.9% and 50% in 33 cases of ADC, respectively, while CK7 and Napsin A had 100% sensitivity. P63 stain had 77% sensitivity and 50% specificity in 15 cases of SCC, while P-40 had 100% sensitivity. The CD56 stain was 100% sensitive in five cases of small cell carcinoma. Conclusion IHC staining on small lung biopsies allows accurate sub-classification of poorly differentiated lung cancers; however, there is still significant variability. Surgical resection specimens can be further classified due to architectural features that biopsies lack. Morphological findings would be beneficial in the development of an algorithm for sub-classifying lung carcinoma using a variety of markers.
Diagnostic utility of immunocytochemistry by using liquid-based cytology (LBC) slides

Ozben Yalcin,Senay Erdogan-Durmus,Enver Yarikkaya

DOI: https://doi.org/10.5603/fhc.97937

Abstract:Introduction: Cytological specimens, such as fine needle aspirations (FNAs) and exfoliative cytology samples, are minimally invasive options for diagnostic purposes. Liquid-based cytology (LBC), originally designed for cervical cytology, has gained prominence as an alternative technique for non-gynecological cytology. Immunocytochemistry (ICC) is an ancillary method used when diagnosis becomes challenging due to morphological overlap or the need for cellular origin clarification. This study aims to assess the diagnostic utility of ICC when applied to LBC slides and evaluate its effectiveness in relation to the waiting (lag) time of residual material. Materials and methods: A total of 74 cases in which ICC was applied to LBC slides were studied over one year in a reference pathology laboratory (Prof. Dr. Cemil Tascioglu, Pathology Laboratory, City Hospital, Istanbul, Turkey). Cases in which immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded cell blocks were excluded. The SurePath PAP method was used for the main LBC cytology slides. For the ICC study, 1-4 PAP-stained LBC slides were obtained from each case's residual material and stained with a primary antibody. Results: The positive immunostaining was obtained in 81% of cases. The samples were categorized into groups based on the waiting time of residual LBC material for ICC analysis: 1-5 days, 6-10 days, 11-20 days, and 21-38 days. Comparative analysis revealed a decline in ICC efficacy as the waiting (lag) time increased. Additionally, a statistically significant difference was observed between the 11-20 days and 21-38 days groups (P < 0.05). An analysis of 142 LBC slides stained by ICC revealed that nuclear markers exhibited higher positivity compared to non-nuclear markers, although no significant difference was detected between the two groups. Conclusions: High positivity rates can be obtained in ICC studies performed on additional slides obtained from residual LBC material within the first 20 days. ICC applied to LBC slides is an important and useful alternative for diagnostic and prognostic markers in cases without a cell block or with a cell block without sufficient number of cells.
Multiplex Intraoperative Rapid Immunohistochemistry with Noncontact Antibody Mixing for Distinguishing the Histologic Phenotype of Lung Cancer

Shoji Kuriyama,Kazuhiro Imai,Hiroshi Nanjo,Yuki Wakamatsu,Shinogu Takashima,Tsubasa Matsuo,Hidenobu Iwai,Ryo Demura,Haruka Suzuki,Yuzu Harata,Sumire Shibano,Akiyuki Wakita,Yusuke Sato,Kyoko Nomura,Yoshihiro Minamiya

DOI: https://doi.org/10.1159/000539640

2024-06-24

Pathobiology

Abstract:Introduction: Determining a surgical strategy for early-stage lung cancer requires an accurate histologic diagnosis. Immunohistochemistry (IHC) enables reliable diagnosis of histological types but requires more time and more tumor tissue slides than hematoxylin and eosin staining. We aimed to assess the clinical validity of a new rapid multiplex IHC technique utilizing alternating current (AC) mixing for intraoperative lung cancer diagnosis. Methods: Forty-three patients who underwent radical resection of lung cancers were enrolled in a retrospective observational study. Frozen sections were prepared from lung tumor samples, and rapid IHC employing AC mixing was implemented alongside a multiplex IHC protocol targeting thyroid transcription factor-1 + cytokeratin 5, desmoglein 3 + Napsin A, and p63 + tripartite motif containing 29. We then evaluated the concordance between intraoperative diagnoses derived from rapid multiplex IHC and final pathology. Results: The concordance rate between the pathological diagnosis made with added rapid multiplex IHC and the final pathology was 93.0% (Cohen’s κ coefficient = 0.860 and 95% CI: 0.727–0.993). When considering only adenocarcinoma and squamous cell carcinoma, the diagnoses were in agreement for all cases. Conclusions: We suggest rapid multiplex IHC as a promising tool for determining surgical strategies for lung tumors.

pathology,cell biology
Abstract 7088: MALDI-IHC high-plex protein biomarker imaging for fast, non-iterative identification of lung carcinoma subtypes

Catherine A. Kita,Kristina Schwamborn,Gargey Yagnik,Kenneth J. Rothschild,Mark J. Lim

DOI: https://doi.org/10.1158/1538-7445.am2024-7088

IF: 11.2

2024-03-23

Cancer Research

Abstract:Lung cancer is the second most common cancer worldwide, with over 2.2 million new cases in 2020 and is the leading cause of cancer-related deaths worldwide. Most lung cancer (80-85%) is non-small cell (NSCLC), comprising mostly adenocarcinoma and squamous cell carcinoma, while roughly 10-15% of lung cancer is small cell lung cancer (SCLC), also termed neuroendocrine lung cancer. Subtype identification is critical for determining treatment, and with limited samples, it is critical to get the most data possible from each tissue section. NSCLC subtypes can be treated with chemotherapy or targeted drugs, whereas SCLC tends to respond best to a combination of chemotherapy and radiation. While there have been many improvements in the detection and treatment of lung carcinoma, the immuno-histochemical (IHC) confirmation of subtype remains a prolonged and often iterative process. To overcome this limitation, we have developed a new IHC approach which uses antibodies labeled with novel photocleavable mass-tags combined with matrix assisted laser desorption ionization (MALDI) mass spectrometry imaging. The approach, termed MALDI-IHC, provides fast (1 hr/cm2 imaging time) and highly multiplexed IHC (100+-plex) without the need for iterative cycling procedures. Here, we present a 20+-plex panel for the determination of subtype in lung cancer. An antibody panel comprised of established clinical biomarkers was developed to differentiate between the lung carcinoma subtypes and provide potentially prognostic information. This included markers for adenocarcinoma (TTF-1, Napsin A), squamous cell carcinoma (p40, CK5), and small cell lung cancer (CD56, Chromogranin A and Synaptophysin), as well as general carcinoma markers for t cells, b cells, macrophages, and fibroblasts These markers were first validated individually by immunofluorescence and then compared to MALDI-IHC on annotated tissues. Here we present an overview of the antibody validation for the 20+-plex lung carcinoma panel. Biomarker presence and peak signal intensity for the various subtypes was then determined using pathologist classified tissues for normal lung, adenocarcinoma, squamous cell carcinoma and small cell lung cancer. We report application of the MALDI-IHC approach to the simultaneous determination of lung carcinoma subtypes on a 99-core human lung tissue microarray (TMA) comprised of normal, normal adjacent, cancer adjacent, and cancerous tissues. Moreover, because MALDI-IHC is a non-destructive process, it can be followed by conventional H&E staining on the same tissue section for accurate co-registration of traditional pathology annotations with the highly multiplexed MALDI-IHC results. In the future, even larger, 100+-plex antibody panels can be used for precision medicine on a wide range of cancers, in order to determine the molecular subtypes and guide treatment paths. Citation Format: Catherine A. Kita, Kristina Schwamborn, Gargey Yagnik, Kenneth J. Rothschild, Mark J. Lim. MALDI-IHC high-plex protein biomarker imaging for fast, non-iterative identification of lung carcinoma subtypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7088.

oncology
Multi-Tissue Controls and Multiplex Immunocytochemistry in Pulmonary Cytology

Antti Vuorisalo,Teppo Haapaniemi,Ivana Kholová

DOI: https://doi.org/10.1159/000540367

2024-07-30

Abstract:Introduction: The World Health Organization 2021 lung cancer classification highlights the central role of immunohistochemistry (IHC) in diagnostic pathology. Despite traditional IHC being essential, its limitation to one marker per tissue section brings challenges, particularly when facing cytological limitedly sized samples. To overcome these challenges, multiplex immunocytochemistry (mICC) techniques offer the simultaneous detection of multiple markers from a single section. These advances complement the highly complex imaging techniques that enable additional analyses of cellular interactions. Methods: The present study outlines a comprehensive mICC methodology of an automated multiplex immunoperoxidase staining method and multiple tissue hybrid controls for ICC/mICC. Protocols are presented in detail and demonstrate a careful approach to optimizing various markers for diagnostic workup including immunotherapy. Conclusion: Multiplex IHC/ICC emerges as a transformative force in biomedical diagnostics and research. Beyond simultaneous marker detection, it unravels complexities within tissues - unveiling co-localization nuances, deciphering expression patterns, and enhancing understanding of cellular populations. As personalized treatments gain prominence, the study emphasizes the heightened importance of diagnostic tools and sample adequacy. The present methodological study, encapsulating an automated multiplex immunoperoxidase staining method, symbolizes a stride towards precision in pulmonary carcinoma diagnosis. Multi-tissue controls represent a key element in quality assurance in pathology laboratories.
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer

Boju Pan,Yuxin Kang,Yan Jin,Lin Yang,Yushuang Zheng,Lei Cui,Jian Sun,Jun Feng,Yuan Li,Lingchuan Guo,Zhiyong Liang

DOI: https://doi.org/10.1186/s12967-021-02898-z

IF: 8.44

2021-06-07

Journal of Translational Medicine

Abstract:Abstract Introduction Programmed cell death ligand-1 (PD-L1) expression is a promising biomarker for identifying treatment related to non-small cell lung cancer (NSCLC). Automated image analysis served as an aided PD-L1 scoring tool for pathologists to reduce inter- and intrareader variability. We developed a novel automated tumor proportion scoring (TPS) algorithm, and evaluated the concordance of this image analysis algorithm with pathologist scores. Methods We included 230 NSCLC samples prepared and stained using the PD-L1(SP263) and PD-L1(22C3) antibodies separately. The scoring algorithm was based on regional segmentation and cellular detection. We used 30 PD-L1(SP263) slides for algorithm training and validation. Results Overall, 192 SP263 samples and 117 22C3 samples were amenable to image analysis scoring. Automated image analysis and pathologist scores were highly concordant [intraclass correlation coefficient (ICC) = 0.873 and 0.737]. Concordances at moderate and high cutoff values were better than at low cutoff values significantly. For SP263 and 22C3, the concordances in squamous cell carcinomas were better than adenocarcinomas (SP263 ICC = 0.884 vs 0.783; 22C3 ICC = 0.782 vs 0.500). In addition, our automated immune cell proportion scoring (IPS) scores achieved high positive correlation with the pathologists TPS scores. Conclusions The novel automated image analysis scoring algorithm permitted quantitative comparison with existing PD-L1 diagnostic assays and demonstrated effectiveness by combining cellular and regional information for image algorithm training. Meanwhile, the fact that concordances vary in different subtypes of NSCLC samples, which should be considered in algorithm development.

medicine, research & experimental
Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer

Kosuke Natsume,Juanjuan Ye,Yuri Mukai,Keiko Yamakawa,Misa Tanimoto,Hiroyuki Ito,Yohei Miyagi,Yataro Daigo,Mariko Muto-Ishizuka,Kyuichi Kadota,Reiji Haba,Futoshi Suizu,KOSUKE NATSUME,JUANJUAN YE,YURI MUKAI,KEIKO YAMAKAWA,MISA TANIMOTO,HIROYUKI ITO,YOHEI MIYAGI,YATARO DAIGO,MARIKO MUTO-ISHIZUKA,KYUICHI KADOTA,REIJI HABA,FUTOSHI SUIZU

DOI: https://doi.org/10.21873/anticanres.16862

2024-02-01

Anticancer Research

Abstract:BACKGROUND/AIM: Immunohistochemical (IHC) staining has been routinely used to distinguish adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of the lungs; however, it is challenging to obtain an accurate diagnosis, especially for cases with discrepancies between IHC and hematoxylin and eosin (H&E) staining results. This study aimed to clarify the clinicopathological characteristics of these discrepant cases.PATIENTS AND METHODS: Tissue microarray specimens from 321 patients with ADC and SCC were used for H&E and IHC staining of thyroid transcription factor 1 (TTF-1), Napsin A, cytokeratin 5/6 (CK5/6), p40, and p63. The pathological diagnosis was made based on (1) H&E, (2) IHC, and (3) both H&E and IHC results. Discrepant cases were defined as those with different diagnoses based on the H&E and IHC results.RESULTS: A total of 32 (10%) discrepant cases were identified. ADC (3.9%) showed fewer discrepant cases than SCC (51%). Discrepant cases of ADC had a significantly higher proportion of poorly differentiated tumors and subtypes of solid and invasive mucinous ADC, and they also had shorter overall and disease-free survival than concordant cases. Solid and invasive mucinous ADC cases showed low positivity for TTF-1 (84% and 40%, respectively) and Napsin A (88% and 80%, respectively), and invasive mucinous ADC cases showed high positivity for CK5/6 (80%). The sensitivity and specificity of TTF-1+Napsin A for ADC were 91% and 83%, respectively, whereas those of CK5/6+p40 for SCC cases were 90% and 96%, respectively.CONCLUSION: Discrepant cases of ADC are associated with solid and invasive mucinous subtypes and shorter survival.

oncology
Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology

Yen-Yu Lin,Lei-Chi Wang,Yu-Han Hsieh,Yu-Ling Hung,Yung-An Chen,Yu-Chieh Lin,Yen-Yin Lin,Teh-Ying Chou

DOI: https://doi.org/10.1186/s12967-022-03335-5

IF: 8.44

2022-03-16

Journal of Translational Medicine

Abstract:Abstract Immune checkpoint blockade therapy has revolutionized non-small cell lung cancer treatment. However, not all patients respond to this therapy. Assessing the tumor expression of immune checkpoint molecules, including programmed death-ligand 1 (PD-L1), is the current standard in predicting treatment response. However, the correlation between PD-L1 expression and anti-PD-1/PD-L1 treatment response is not perfect. This is partly caused by tumor heterogeneity and the common practice of assessing PD-L1 expression based on limited biopsy material. To overcome this problem, we developed a novel method that can make formalin-fixed, paraffin-embedded tissue translucent, allowing three-dimensional (3D) imaging. Our protocol can process tissues up to 150 μm in thickness, allowing anti-PD-L1 staining of the entire tissue and producing high resolution 3D images. Compared to a traditional 4 μm section, our 3D image provides 30 times more coverage of the specimen, assessing PD-L1 expression of approximately 10 times more cells. We further developed a computer-assisted PD-L1 quantitation method to analyze these images, and we found marked variation of PD-L1 expression in 3D. In 5 of 33 needle-biopsy-sized specimens (15.2%), the PD-L1 tumor proportion score (TPS) varied by greater than 10% at different depth levels. In 14 cases (42.4%), the TPS at different depth levels fell into different categories (< 1%, 1–49%, or ≥ 50%), which can potentially influence treatment decisions. Importantly, our technology permits recovery of the processed tissue for subsequent analysis, including histology examination, immunohistochemistry, and mutation analysis. In conclusion, our novel method has the potential to increase the accuracy of tumor PD-L1 expression assessment and enable precise deployment of cancer immunotherapy.

medicine, research & experimental
Integrating AI-powered digital pathology and imaging mass cytometry identifies key classifiers of tumor cells, stroma, and immune cells in non-small cell lung cancer

Alessandra Rigamonti,Marika Viatore,Rebecca Polidori,Daoud Rahal,Marco Erreni,Maria Rita. Fumagalli,Damiano Zanini,Andrea Doni,Anna Rita. Putignano,Paola Bossi,Emanuele Voulaz,Marco Alloisio,Sabrina Rossi,Paolo Andrea. Zucali,Armando Santoro,Vittoria Balzano,Paola Nisticò,Friedrich Feuerhake,Alberto Mantovani,Massimo Locati,Federica Marchesi

DOI: https://doi.org/10.1158/0008-5472.can-23-1698

IF: 11.2

2024-02-06

Cancer Research

Abstract:Artificial intelligence (AI)-powered approaches are becoming increasingly used as histopathological tools to extract sub-visual features and improve diagnostic workflows. On the other hand, hi-plex approaches are widely adopted to analyze the immune ecosystem in tumor specimens. Here, we aimed at combining AI-aided histopathology and imaging mass cytometry (IMC) to analyze the ecosystem of non-small cell lung cancer (NSCLC). An AI-based approach was used on H&E sections from 158 NSCLC specimens to accurately identify tumor cells, both adenocarcinoma and squamous carcinoma cells, and to generate a classifier of tumor cell spatial clustering. Consecutive tissue sections were stained with metal-labeled antibodies and processed through the IMC workflow, allowing quantitative detection of 24 markers related to tumor cells, tissue architecture, CD45+ myeloid and lymphoid cells, and immune activation. IMC identified 11 macrophage clusters that mainly localized in the stroma, except for S100A8+ cells, which infiltrated tumor nests. T cells were preferentially localized in peritumor areas or in tumor nests, the latter being associated with better prognosis, and they were more abundant in highly clustered tumors. Integrated tumor and immune classifiers were validated as prognostic on whole slides. In conclusion, integration of AI-powered H&E and multiparametric IMC allows investigation of spatial patterns and reveals tissue relevant features with clinical relevance.

oncology
The application of ThinPrep cytology in the diagnosis of superficial tumors

JI Hong-ai,WANG Jing-hua,ZHOU Xiao-jun,JI Yun,LIU Hong-juan,WU Wei-lin,QI Zheng-mao

DOI: https://doi.org/10.3969/j.issn.1008-8199.2006.01.021

2006-01-01

Abstract:Objective: To investigate the advantage of ThinPrep cytological test in tumor diagnosis by fine needle aspiration cytology. Methods: Using fine needle aspiration for smears,some of smears were made in conventional smears,the remains aspirating needles were washed with a transport washing solution.ThinPrep slides were made using the ThinPrep Processor. Results: In 84 cases FNA samples,49 cases were breast,29 cases were lymph node and 6 cases were others.Comparing with conventionally prepared specimens,ThinPrep processed samples showed the advantage in sensitivity or specificity.The lack of cellular debris,blood and exudates improve the ability to detect cellular abnormalities and speed up the time required for screening in ThinPrep processed samples.Rapid cell transfer from the sampling device to the transporing fluid containing the fixative ensure preservation of cell details with minimal artifactual changes. Conclusion: The use of Thinprep and by combination of FNAC and immunocytochemistry cytopathological diagnosis can be improved significantly.

Protein composition of cerebrospinal fluid in the developing chick embryo.

Artificial Classification of Cervical Squamous Lesions in ThinPrep Cytologic Tests Using a Deep Convolutional Neural Network.

The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma

Diagnostic and Predictive Immunocytochemistry in Lung Cancer

Recommendations for immunocytochemistry in lung cancer typing: An update on a resource-efficient approach with large-scale comparative Bayesian analysis

Immunocytochemistry for predictive biomarker testing in lung cancer cytology

Nonlinear and Time-Varying Dynamical Models of Human Operators in Manual Control Systems

A technique to improve diagnostic information from fine-needle aspirations: immunohistochemistry on cytoscrape

Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans.

PUB015 the Use of Immunohistochemistry Improves the Diagnosis of SCLC. an International Reproducibility Study in a Demanding Set of Cases

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases

Accuracy of Classifying Lung Carcinoma Using Immunohistochemical Markers on Limited Biopsy Material: A Two-Center Study

Diagnostic utility of immunocytochemistry by using liquid-based cytology (LBC) slides

Multiplex Intraoperative Rapid Immunohistochemistry with Noncontact Antibody Mixing for Distinguishing the Histologic Phenotype of Lung Cancer

Abstract 7088: MALDI-IHC high-plex protein biomarker imaging for fast, non-iterative identification of lung carcinoma subtypes

Multi-Tissue Controls and Multiplex Immunocytochemistry in Pulmonary Cytology

Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer

Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer

Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology

Integrating AI-powered digital pathology and imaging mass cytometry identifies key classifiers of tumor cells, stroma, and immune cells in non-small cell lung cancer

The application of ThinPrep cytology in the diagnosis of superficial tumors